Highlights Landos Biopharma, Inc.

Equities

LABP

US5150692011

Market Closed - Nasdaq Other stock markets 02:00:01 14/05/2024 am IST			5-day change	1st Jan Change
22.2 ^USD	-0.56%		+0.25%	+506.69%

09/05	Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/04	North American Morning Briefing : Stocks Seen -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Deals of the day-Mergers and acquisitions	26/03	RE
Sector Update: Health Care Stocks Decline Late Afternoon	26/03	MT
Top Midday Gainers	25/03	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	25/03	MT
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump	25/03	MT
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie	25/03	DJ
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million	25/03	DJ
AbbVie to Acquire Landos Biopharma for About $137.5 Million	25/03	MT
AbbVie to Acquire Landos Biopharma for About $137.5 Million	25/03	MT
AbbVie to buy Landos to expand pipeline of immunity-related illnesses	25/03	RE
AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.	25/03	CI
Landos Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Landos Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03	CI
Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn?s and Colitis	21/11	CI
Landos Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting	23/23/23	CI
Landos Biopharma Enters Research Collaboration to Investigate Effects of NX-13 on Epithelial Cells	14/23/14	MT
Landos Biopharma, Inc. Announces Strategic Research Collaboration with Ku Leuven and University Hospitals Leuven to Further Characterize the Effects of Nx-13 on Epithelial Cells	14/23/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Landos Biopharma, Inc.

Equities

LABP

US5150692011

Highlights

Filters